Date: November 13, 2019 at 2PM ET (11AM PT)Please join Abveris' Chief Operating Officer, Tracey Mullen, for our webinar to learn more about our premier anti-idiotype antibody discovery service for mAbs, bispecifics, scFvs, VHHs, and more.
Benefits of our approach:
- Rapid reagent generation timelines
- Maximal epitope coverage with DiversimAb technology
- Highly sensitive specificity screening
- Identification of high-affinity mAbs
- Neutralizing and non-neutralizing mAbs
- Flexible deliverable strategies
- All work done in the USA
Abveris has the expertise and technology advantages required to develop high-quality reagents to the trickiest biotherapeutic molecules. Join our webinar to learn more.